# India Car T Cell Therapy Market > India CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), and By End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 15.48% - **2024:** $ 461.9 Million - **2025:** $ 533.4 Million - **2035:** $ 2,249.8 Million - **Key Players:** Gilead Sciences (US), Novartis (CH), Bristol-Myers Squibb (US), Celgene (US), Amgen (US), Merck & Co. (US), AstraZeneca (GB), Bluebird Bio (US), Celyad Oncology (BE) **Report ID:** MRFR/Pharma/48115-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-car-t-cell-therapy-market-49871 --- ## Market Summary ## **India****CAR T****Cell Therapy Market Overview** As per MRFR analysis, the India CAR T Cell Therapy Market Size was estimated at 400 (USD Million) in 2023.The India CAR T Cell Therapy Market is expected to grow from 462(USD Million) in 2024 to 2,070 (USD Million) by 2035. The India CAR T Cell Therapy Market CAGR (growth rate) is expected to be around 14.607% during the forecast period (2025 - 2035). ### **Key India****CAR T****Cell Therapy Market Trends Highlighted** The rising incidence of cancer and greater acceptance of cutting-edge cancer treatment alternatives are driving the market for CAR T cell therapy in India. In order to support the development and accessibility of CAR T cell therapies, the Indian government has been aggressively supporting biotechnology research and development. Patient access to treatment is improved by encouraging local enterprises to participate in CAR T cell therapy through favorable regulatory frameworks and programs, such as the National Biotechnology Development Strategy. Furthermore, the growth of public-private partnerships in India's healthcare industry is opening doors for cooperation and resulting in the creation of affordable CAR T treatments that are suited to the requirements of the Indian populace. The ability of CAR T therapy to target particular cancer features is consistent with recent trends showing an increase in interest in personalized medicine methods in oncology. Clinical studies for CAR T therapies are receiving more attention from hospitals and research institutes, which improves the chances of their commercialization in India. The market is also seeing a noticeable trend of consolidation as larger companies look to buy out smaller businesses with cutting-edge technology. In addition to enhancing market capacities, this trend speeds up the creation of innovative CAR T treatments. The goal of educational initiatives is to educate patients and healthcare professionals about CAR T cell therapies as more healthcare providers become aware of its potential, which should increase their acceptance and use. There are chances to make CAR T therapies available to a wider range of people because to improvements in manufacturing techniques and cost savings. All things considered, the increasing focus on cutting-edge therapeutic approaches along with encouraging government regulations sets the Indian CAR T cell therapy market for further growth and change. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **India****CAR T****Cell Therapy Market Drivers** Rising Incidence of Cancer in India The increasing prevalence of cancer in India is a significant driver for the India CAR T Cell Therapy Market. The Indian Council of Medical Research reported that there were approximately 1.45 million new cancer cases diagnosed in India in 2020, with a projected increase of about 12% in the next decade. This escalation in cancer rates necessitates innovative treatment options, pushing healthcare providers to explore advanced therapies like CAR T Cell Therapy. Major healthcare organizations, such as Tata Memorial Centre and All India Institute of Medical Sciences, are actively involved in research and clinical trials for CAR T Cell therapies, thereby facilitating growth in the industry. Furthermore, with the rising population, which is expected to surpass 1.4 billion by 2025, the demand for effective cancer therapies will continue to surge, propelling the India CAR T Cell Therapy Market forward. Investment in Research and Development There is a growing emphasis on Research and Development in India, particularly in the field of CAR T Cell Therapy. The Indian government, through initiatives such as the Atal Innovation Mission, is investing significantly in biotechnology and healthcare research. For instance, reports indicate that approximately USD 1.3 billion was allocated to healthcare innovation in recent budgets. This governmental support is crucial in fostering local startups and established organizations to explore CAR T technologies, leading to advancements in treatment efficacy and safety. Major pharmaceutical companies like Biocon and Dr. Reddy's Laboratories are also dedicating resources to develop CAR T Cell therapies, thus enhancing the industry's ecosystem. Regulatory Support for Advanced Therapies The regulatory landscape in India has become increasingly conducive to the approval and implementation of advanced therapies, including CAR T Cell Therapy. The Central Drugs Standard Control Organization has established guidelines to expedite the approval process for new and innovative therapies. This regulatory support encourages pharmaceutical companies and research institutions to invest in CAR T Cell innovations. With an increased focus on personalized medicine, as highlighted in the National Health Policy, this demonstrates a clear direction for the industry. In addition, the recent legislations aimed at reducing the bureaucracy surrounding clinical trials have further motivated companies to proceed with CAR T Cell developments in India. ## **India****CAR T****Cell Therapy Market Segment Insights** ### **CAR T****Cell Therapy Market Therapeutic Area Insights** The India CAR T Cell Therapy Market is witnessing significant growth within the realm of Therapeutic Areas, driven by the increasing prevalence of various diseases that require innovative treatment solutions. In recent years, the Oncology segment has emerged as a focal point due to the escalating rates of cancer in India, which has necessitated the development of advanced therapies like CAR T Cell Therapy. Oncology treatments are particularly crucial as traditional approaches often fall short in efficacy, prompting a shift towards personalized therapies that enhance patient outcomes. Furthermore, advancements in Research and Development within this field are facilitating the emergence of novel CAR T Cell therapies designed to target specific cancer types more effectively. In parallel, Autoimmune Diseases represent a vital aspect of the therapeutic landscape that CAR T Cell Therapy aims to address. The rising incidence of conditions like rheumatoid arthritis and lupus underscores the importance of developing targeted therapies that can modulate or restore immune responses. CAR T Cell Therapy has the potential to revolutionize the treatment of these diseases, recognizing that a one-size-fits-all approach may be inadequate. The adaptability of CAR T Cell Therapy in targeting aberrant immune responses signifies its relevance in this sector, expanding the therapeutic possibilities for patients who may not respond to conventional treatments. Additionally, the impact of Infectious Diseases within the scope of CAR T Cell Therapy cannot be overlooked. As India grapples with the burden of various infectious diseases, the application of CAR T technology holds promise in developing targeted treatment strategies that could enhance immunity against specific pathogens. For instance, leveraging CAR T Cell Therapy for viral infections could pave the way for new modalities that offer patients more effective treatment options against enduring health crises. The ongoing investments in healthcare initiatives, alongside governmental support for innovative therapies, bolster this segment's growth. In summary, all these therapeutic areas showcase the potential of CAR T Cell Therapy to address unmet medical needs and highlight the need for ongoing Research and Development. With an expanding patient pool and increasing prevalence of diseases requiring innovative approaches, the Therapeutic Area segment within the India CAR T Cell Therapy Market is poised for sustained growth. The confluence of technological advancements with a pressing need for new therapies further underscores the significance of this market segment in addressing critical health challenges faced in India today. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **CAR T****Cell Therapy Market Cell Source Insights** The Cell Source segment of the India CAR T Cell Therapy Market is a significant area, showcasing diverse approaches to cancer treatment. Within this segment, Autologous CAR T Cell therapies have gained prominence as they utilize a patient's own T cells, offering a personalized treatment option that reduces the risk of rejection and enhances efficacy. Allogeneic therapies, sourced from healthy donors, are gaining traction due to their potential to provide off-the-shelf products, which streamline the treatment process and offer timely intervention for patients with urgent needs. Meanwhile, gene-edited T cells represent cutting-edge advancements in biotechnology, allowing for optimized T cell functionality by modifying their characteristics for enhanced tumor targeting. The growing demand for innovative cancer treatments in India is driven by an increase in cancer incidences and advancements in Research and Development, with the government promoting initiatives to boost healthcare innovation. As the need for personalized and accessible cancer therapies continues to rise, the importance of Cell Source options in the India CAR T Cell Therapy Market is expected to expand, catering to diverse patient needs and improving treatment outcomes. ### **CAR T****Cell Therapy Market Indication Insights** The India CAR T Cell Therapy Market is experiencing a significant transformation, especially within the Indication segment, which comprises various critical applications. Notably, Acute Lymphoblastic Leukemia has emerged as a major focus area, benefiting from advancements in personalized medicine that cater to the unique genetic characteristics of patients. Similarly, non-Hodgkin lymphoma holds substantial importance, with increasing awareness and early diagnosis driving the demand for effective therapies. Multiple Myeloma is also gaining attention due to the rising prevalence of this hematological condition, prompting healthcare providers to seek innovative treatment solutions. These indications not only highlight the therapeutic potential of CAR T Cell Therapy but also align with the growing investment in Research and Development initiatives aimed at improving patient outcomes. The government's support for advanced cancer therapies and increasing collaboration among pharmaceutical companies foster an environment conducive to the rapid expansion of these targeted treatments in India. Thus, as the India CAR T Cell Therapy Market evolves, the significance of specific indications underscores the broader trends in cancer care tailored to meet regional healthcare needs. ### **CAR T****Cell Therapy Market****End-user****Insights** The End-user segment of the India CAR T Cell Therapy Market showcases a diverse landscape that is crucial for the effective deployment of innovative therapies. Hospitals hold a significant role as primary providers of CAR T Cell Therapy, offering specialized services and infrastructure to manage complex treatments and patient care. Research Institutes are pivotal in advancing clinical trials and developing novel therapies, contributing to the industry's progression and enhancing treatment options available for cancer patients. Meanwhile, Cancer Treatment Centers are tailored environments focused on comprehensive oncology care, providing personalized approaches that cater to the unique needs of patients undergoing CAR T Cell Therapy. The synergy among these entities is essential as they collaborate to drive research advancements and improve patient outcomes. In India, a robust healthcare system and increasing investment in cancer care facilities highlight the ongoing trends and growth potential within this market segment. The shift towards personalized medicine, driven by technological innovations, coupled with rising cancer incidence, underscores the importance of these End-users in fostering a sustainable and effective CAR T Cell Therapy landscape in the country. ## **India****CAR T****Cell Therapy Market Key Players and Competitive Insights** The India CAR T Cell Therapy Market is becoming increasingly competitive as advancements in biotechnology continue to reshape cancer treatment options. This market has witnessed significant growth due to the rising incidence of hematological malignancies and the launching of innovative therapies targeting such conditions. The competition is characterized by both domestic and international players striving to establish their presence and gain market share. Companies are focusing on research and development to enhance their treatment efficacy, reduce costs, and ensure accessibility to patients. Furthermore, collaborations and partnerships between pharmaceutical firms, research institutes, and healthcare providers are being forged to bolster product offerings and improve patient outcomes, adding complexity to the competitive landscape. Legend Biotech is emerging as a key player in the India CAR T Cell Therapy Market, leveraging its robust research capabilities and innovative treatment solutions targeting cancers. The company has established a promising market presence, primarily focusing on its flagship CAR T-cell therapy products, which have shown significant clinical efficacy in treating certain types of blood cancers. The strength of Legend Biotech lies in its commitment to maintaining high standards of research and development, coupled with strategic alliances that enhance its technological capabilities. By tapping into the growing demand for advanced cancer treatments in India, Legend Biotech is well-positioned to expand its market outreach and contribute positively to the evolving therapeutic landscape. Celgene is another prominent entity in the India CAR T Cell Therapy Market, recognized for its contributions to oncology and hematology. With a diverse portfolio of key products that includes advanced therapies for hematological cancers, Celgene has successfully established a stronghold within the Indian market. Its ability to innovate and adapt to local healthcare needs ensures that Celgene remains competitive. Strengths of the company encompass not only its well-researched treatment protocols but also its ongoing initiatives in mergers and acquisitions aimed at enhancing its technological capabilities and expanding its product portfolio. By aligning with local partners and engaging in strategic collaborations, Celgene has reinforced its commitment to delivering state-of-the-art therapies to Indian patients, fostering long-term growth in the CAR T Cell Therapy sector. **Key Companies in the India****CAR T****Cell Therapy Market Include** ## **India****CAR T****Cell Therapy****Market****Developments** The India CAR T Cell Therapy Market has recently experienced significant advancements, with multiple key players actively enhancing their presence. In September 2023, Legend Biotech announced its plans to bolster its Research and Development efforts in Mumbai, aiming to accelerate the development of cell therapies. Celgene's collaboration with local biotechnology firms is set to transition to clinical trials focused on hematological cancers. Similarly, Novartis is finalizing its partnership with leading hospitals for CAR T cell treatments, expected to launch by early 2024. Major acquisitions have also shaped the market landscape; in July 2023, Gilead Sciences acquired a smaller biotech firm specializing in immunotherapies, which strengthens its foothold in the Indian market. Companies like Kite Pharma and Bristol-Myers Squibb continue to expand their clinical trial networks in India, emphasizing the growing demand for advanced cancer treatments. The market valuation has surged, driven by increasing investments in biotechnology and government support for innovative therapies. With logistical advancements and collaborations, the therapeutic options for patients in India are broadening, marking a transformative period for the CAR T Cell Therapy landscape within the region. ## **India****CAR T****Cell Therapy Market Segmentation Insights** ### **CAR T****Cell Therapy Market Therapeutic Area****Outlook** ### **CAR T****Cell Therapy Market Cell Source****Outlook** ### **CAR T****Cell Therapy Market Indication****Outlook** ### **CAR T****Cell Therapy Market****End-user****Outlook** ## Market Drivers ### Supportive Regulatory Environment The regulatory environment in India is increasingly supportive of innovative therapies, including CAR T-cell therapy. The Central Drugs Standard Control Organization (CDSCO) has streamlined the approval process for advanced therapies, which is likely to encourage more companies to invest in CAR T-cell products. Recent initiatives have reduced the time for clinical trial approvals by approximately 30%, facilitating faster access to new treatments for patients. This supportive regulatory framework is expected to foster innovation and growth within the car t-cell-therapy market, as more therapies gain approval and enter the market, ultimately benefiting patients in need of advanced cancer treatments. ### Growing Awareness and Patient Advocacy Awareness of CAR T-cell therapy is increasing among patients and healthcare professionals in India. Patient advocacy groups are playing a crucial role in educating the public about the benefits and availability of CAR T-cell therapies. This heightened awareness is likely to lead to increased demand for such treatments, thereby propelling the car t-cell-therapy market forward. Reports indicate that approximately 60% of oncologists in India are now familiar with CAR T-cell therapy, compared to just 30% a few years ago. As more patients become informed about their treatment options, the market is expected to witness a significant uptick in the number of patients seeking CAR T-cell therapy. ### Rising Incidence of Hematological Malignancies The rising incidence of hematological malignancies in India is a significant driver for the car t-cell-therapy market. With an estimated 200,000 new cases of blood cancers reported annually, the demand for effective treatment options is on the rise. CAR T-cell therapy has shown promising results in treating conditions such as acute lymphoblastic leukemia and non-Hodgkin lymphoma, which are prevalent in the Indian population. As healthcare providers seek to offer more effective therapies, the car t-cell-therapy market is likely to expand to meet this growing need. The potential for CAR T-cell therapy to provide long-term remission in patients is further fueling interest in this innovative treatment. ### Increasing Investment in Healthcare Infrastructure The car t-cell-therapy market in India is seeing increased investment to enhance healthcare infrastructure. Government initiatives and private sector funding are contributing to the establishment of advanced treatment facilities. For instance, the Indian government has allocated approximately $1.5 billion to improve cancer care services, which includes the integration of innovative therapies like CAR T-cell therapy. This investment is likely to facilitate better access to cutting-edge treatments. Furthermore, the establishment of specialized centers for CAR T-cell therapy is expected to enhance patient outcomes and increase the overall adoption of this revolutionary treatment modality. ### Technological Advancements in Treatment Modalities The car t-cell-therapy market is being significantly influenced by rapid technological advancements in treatment modalities. Innovations in genetic engineering and cell processing techniques are enhancing the efficacy and safety of CAR T-cell therapies. For example, the introduction of automated cell processing systems has reduced the time required for manufacturing CAR T-cells, making treatments more accessible. Additionally, the cost of CAR T-cell therapy is projected to decrease by approximately 20% over the next few years due to these advancements. Such technological progress is likely to attract more healthcare providers to adopt CAR T-cell therapies, thereby expanding the market. ## Future Outlook The [CAR T Cell Therapy Market](https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102) in India is projected to grow at a 15.48% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and supportive regulatory frameworks. **New opportunities:** - Development of personalized CAR T-cell therapies for niche cancer types. - Expansion of manufacturing capabilities to reduce production costs. - Strategic partnerships with hospitals for integrated treatment programs. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in innovative cancer therapies. ## Segment Insights ### By Therapeutic Area: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) In the India car t-cell-therapy market, Oncology leads the segment with the largest market share, reflecting the substantial demand for novel cancer treatments. Autoimmune Diseases, while smaller in market size, showcase a rapid increase in adoption as innovative therapies emerge to combat chronic conditions. Infectious Diseases represent a vital yet more niche area, capturing the attention of researchers and developers aiming to address global health challenges. Current growth trends indicate a significant rise in investments directed toward Oncology, driven by advancements in CAR T-cell technology and increasing incidence rates of cancer. Meanwhile, the Autoimmune Diseases segment is gaining traction due to the growing awareness of these conditions and the need for effective therapies, underscoring a shift in focus towards personalized medicine. The infectious diseases segment, while trailing in growth, is being spurred by ongoing research and a keen interest in addressing severe health crises. Oncology (Dominant) vs. Autoimmune Diseases (Emerging) Oncology remains the dominant segment within the India car t-cell-therapy market, characterized by highly aggressive research and development activities targeting various cancer types. This segment benefits from substantial collaboration between biopharmaceutical companies and academic institutions, fostering innovation and accelerating product development timelines. Conversely, the Autoimmune Diseases segment is emerging as a vital area of therapeutic exploration, leveraging the success of previously established CAR T-cell therapies. The unique complexities of autoimmune disorders necessitate tailored approaches, driving interest from both investors and clinicians. As more breakthroughs are made in the science of CAR T-cell applications for autoimmune conditions, this segment is poised for exponential growth, expanding treatment options for patients and enhancing market dynamics. ### By Cell Source: Autologous (Largest) vs. Allogeneic (Fastest-Growing) In the India car t-cell-therapy market, the cell source segment showcases a notable distribution of market shares among autologous, allogeneic, and gene-edited therapies. Autologous therapies dominate the segment, capturing the largest market share due to their tailored treatment approach and effectiveness in addressing various hematological malignancies. Meanwhile, allogeneic therapies are rapidly gaining traction, characterized by their ability to provide off-the-shelf treatment options that enhance accessibility and reduce treatment waiting times. Growth trends in this segment are primarily driven by increasing investments in research and development, along with the growing prevalence of cancer. The adoption of allogeneic therapies is particularly noticeable as healthcare providers seek to leverage their scalability and cost-effectiveness. Moreover, advancements in gene-editing technologies are propelling the gene-edited segment, creating opportunities for new treatments that could further transform the therapeutic landscape. Autologous (Dominant) vs. Allogeneic (Emerging) Autologous therapies are currently the dominant force in the car t-cell therapy market, utilizing a patient's own T-cells to create personalized treatment regimens. This approach not only yields higher success rates but also mitigates the risk of graft-versus-host disease, making it particularly appealing for patients. On the other hand, allogeneic therapies are emerging as a viable alternative, leveraging donor T-cells to provide quicker treatment solutions. Their ability to be mass-produced and stored opens the door for broader application across various patient demographics, catering to those who may be unable to wait for custom treatments. Collectively, these two segments reflect the dynamic nature of the market, as they fulfill distinct patient needs and contribute to overall therapeutic advancements. ### By Indication: Acute Lymphoblastic Leukemia (Largest) vs. Multiple Myeloma (Fastest-Growing) In the India car t-cell-therapy market, Acute Lymphoblastic Leukemia (ALL) holds the largest market share due to its high prevalence and increasing number of treatment approvals. This segment has garnered significant attention from healthcare providers and researchers alike, leading to greater investment and innovation within the therapy space. Non-Hodgkin Lymphoma also contributes to the market but is comparatively smaller than ALL, while Multiple Myeloma is rapidly climbing, driven by advancements in targeted therapies. The growth of the segments is driven by increasing awareness of CAR T-cell therapies, along with a rise in the diagnosed cases of blood cancers. Regulatory approvals and clinical successes are indicating a promising future for these therapies in treating ALL and Multiple Myeloma. Furthermore, the establishment of specialized treatment centers is likely to boost the accessibility of these therapies, thereby enhancing their adoption levels across the segment. Acute Lymphoblastic Leukemia: Dominant vs. Multiple Myeloma: Emerging Acute Lymphoblastic Leukemia (ALL) represents a dominant force within the India car t-cell-therapy market, characterized by a strong therapeutic pipeline and extensive research efforts. Its established protocols and proven efficacy contribute to its dominant position. Conversely, Multiple Myeloma is emerging rapidly, propelled by breakthroughs in CAR T-cell therapy that offer renewed hope for patients. With increasing clinical trial activity and heightened investment in research, the therapeutic landscape for Multiple Myeloma is evolving quickly. As treatment modalities expand, both segments exhibit unique characteristics: ALL's strength lies in its established market presence, while Multiple Myeloma's dynamism is attributed to innovative therapies that are gaining traction. ### By End User: Hospitals (Largest) vs. Cancer Treatment Centers (Fastest-Growing) In the India car t-cell-therapy market, hospitals dominate the end-user segment, capturing the largest market share due to their established infrastructure and capability to deliver advanced treatment options. This segment benefits from an integrated system of care, allowing for enhanced patient management and follow-up. On the other hand, cancer treatment centers are rapidly gaining traction as they focus specifically on oncology care, providing targeted therapies that cater exclusively to cancer patients while delivering personalized treatment plans. The growth trends within this segment are influenced by factors such as technological advancements in treatment methodologies and increasing collaborations among healthcare providers. As awareness about car t-cell therapies expands, both hospitals and cancer treatment centers are investing in specialized training and resources to accommodate the evolving landscape. Additionally, government initiatives aimed at improving cancer care accessibility contribute to the expansion of these end-user entities in the market. Hospitals (Dominant) vs. Research Institutes (Emerging) Hospitals represent the dominant end-user segment in the India car t-cell-therapy market, primarily due to their robust infrastructure and comprehensive capabilities for administering complex therapies. These facilities are well-equipped to handle the logistics and patient management associated with car t-cell treatments. Conversely, research institutes are emerging as critical players, focusing on innovative research and development of new therapies. Their contributions to clinical trials and advancements in car t-cell treatments foster collaboration with hospitals, enabling a smoother transition of new therapies from laboratory to patient care. While hospitals provide thorough care and comprehensive treatment options, research institutes are poised at the forefront of technological advancement and are essential for future innovations in cancer therapy. ## Competitive Benchmarking The car t-cell-therapy market in India is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a growing emphasis on personalized medicine. Major players such as Gilead Sciences (US), Novartis (CH), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Gilead Sciences (US) focuses on expanding its product portfolio through research and development, while Novartis (CH) emphasizes strategic collaborations to enhance its therapeutic offerings. Bristol-Myers Squibb (US) is leveraging its strong pipeline and established market presence to drive growth, indicating a trend towards consolidation and collaboration among key players, which collectively shapes a competitive environment that is both concentrated and evolving.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also aligns with regulatory requirements in India. The market structure appears moderately fragmented, with a few dominant players exerting considerable influence while allowing room for emerging companies to carve out niches. The collective strategies of these key players suggest a concerted effort to optimize operations and enhance competitive positioning. In October Gilead Sciences (US) announced a partnership with a leading Indian biotechnology firm to co-develop a novel CAR T-cell therapy targeting hematological malignancies. This collaboration is strategically significant as it not only accelerates Gilead's entry into the Indian market but also leverages local expertise to navigate regulatory landscapes more effectively. Such partnerships are likely to enhance Gilead's competitive edge in a rapidly evolving market. In September Novartis (CH) launched a new CAR T-cell therapy in India, following successful clinical trials. This launch is pivotal as it underscores Novartis's commitment to addressing unmet medical needs in the region. By introducing innovative therapies, Novartis aims to solidify its market leadership and respond to the increasing demand for advanced cancer treatments. In August Bristol-Myers Squibb (US) expanded its manufacturing capabilities in India, investing approximately $50 million in a new facility dedicated to CAR T-cell production. This strategic move is indicative of the company's long-term vision to enhance its operational capacity and ensure a reliable supply of therapies. Such investments reflect a broader trend of companies prioritizing local production to mitigate supply chain risks and improve market responsiveness. As of November current competitive trends in the car t-cell-therapy market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, facilitating knowledge sharing and resource optimization among companies. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies will need to invest in cutting-edge technologies and foster collaborative relationships to maintain a competitive edge in this rapidly advancing market. ## Recent News & Developments The India CAR T Cell Therapy Market has recently experienced significant advancements, with multiple key players actively enhancing their presence. In September 2023, Legend Biotech announced its plans to bolster its Research and Development efforts in Mumbai, aiming to accelerate the development of cell therapies. Celgene's collaboration with local biotechnology firms is set to transition to clinical trials focused on hematological cancers. Similarly, Novartis is finalizing its partnership with leading hospitals for CAR T cell treatments, expected to launch by early 2024. Major acquisitions have also shaped the market landscape; in July 2023, Gilead Sciences acquired a smaller biotech firm specializing in immunotherapies, which strengthens its foothold in the Indian market. Companies like Kite Pharma and Bristol-Myers Squibb continue to expand their clinical trial networks in India, emphasizing the growing demand for advanced cancer treatments. The market valuation has surged, driven by increasing investments in biotechnology and government support for innovative therapies. With logistical advancements and collaborations, the therapeutic options for patients in India are broadening, marking a transformative period for the CAR T Cell Therapy landscape within the region. ## **India****CAR T** ## Report Scope | MARKET SIZE 2024 | 461.9(USD Million) | | --- | --- | | MARKET SIZE 2025 | 533.4(USD Million) | | MARKET SIZE 2035 | 2249.8(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.48% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Gilead Sciences (US), Novartis (CH), Bristol-Myers Squibb (US), Celgene (US), Amgen (US), Merck & Co. (US), AstraZeneca (GB), Bluebird Bio (US), Celyad Oncology (BE) | | Segments Covered | Therapeutic Area, Cell Source, Indication, End User | | Key Market Opportunities | Advancements in personalized medicine and regulatory support enhance growth potential in the car t-cell-therapy market. | | Key Market Dynamics | Rising investment in Research and Development drives innovation in the car T-cell therapy market. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India car t-cell-therapy market?** A: The market valuation was $461.9 Million in 2024. **Q: What is the projected market size for the India car t-cell-therapy market by 2035?** A: The market is projected to reach $2249.8 Million by 2035. **Q: What is the expected CAGR for the India car t-cell-therapy market during the forecast period?** A: The expected CAGR is 15.48% from 2025 to 2035. **Q: Which therapeutic areas are driving the India car t-cell-therapy market?** A: Oncology, with a valuation of $1340.0 Million, is a key driver, alongside autoimmune diseases and infectious diseases. **Q: What are the leading cell sources in the India car t-cell-therapy market?** A: Autologous cells lead with $1135.0 Million, followed by allogeneic and gene-edited sources. **Q: What indications are most prevalent in the India car t-cell-therapy market?** A: Acute lymphoblastic leukemia and non-Hodgkin lymphoma each account for $676.67 Million, while multiple myeloma is valued at $896.46 Million. **Q: Who are the key players in the India car t-cell-therapy market?** A: Key players include Gilead Sciences, Novartis, Bristol-Myers Squibb, and others. **Q: What is the market share of hospitals as an end user in the India car t-cell-therapy market?** A: Hospitals represent a significant share with a valuation of $682.56 Million. **Q: How do research institutes contribute to the India car t-cell-therapy market?** A: Research institutes contribute with a valuation of $341.28 Million. **Q: What is the market valuation for cancer treatment centers in the India car t-cell-therapy market?** A: Cancer treatment centers have a valuation of $1225.96 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-car-t-cell-therapy-market-49871*